Company intelligence / Profile preview

Dimera

Portland, Oregon, United Statesdimera.aremond.com ↗

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Dimera developed therapies targeting heart and blood vessel diseases, with at least one candidate advanced to late-stage clinical trial planning. The company has focused on safe and effective medicines for reducing risk in heart disease, including chest pain in women. As of 2008–2024, it was seeking substantial funding ($40M) to survive and mount a pivotal trial; more recent clinical results are not publicly available.[6]

Therapeutic areas: Cardiovascular
Modalities: Small moleculeGene therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Dimera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dimera.

Explore the full profile